Literature DB >> 16807854

Emergence of carbapenem resistance in Acinetobacter baumannii recovered from blood cultures in Australia.

Anton Y Peleg1, Clare Franklin, Jan M Bell, Denis W Spelman.   

Abstract

We describe the first emergence of carbapenem-resistant Acinetobacter baumannii in Australia. Ninety A. baumannii isolates recovered from cultures of blood specimens from 69 patients were analyzed. Overall, 58 isolates (64%) were resistant to meropenem. The chi 2 test for linear trend revealed that emergence of carbapenem resistance was statistically significant during the 32-month study period. Selected isolates were of the same clonal type, and no genes encoding carbapenemases were identified.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16807854     DOI： 10.1086/507012

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN： 0899-823X            Impact factor:   3.254


  13 in total

1.  Clonal spread of imipenem-resistant Acinetobacter baumannii among different cities of China.

Authors:  Hua Zhou; Qing Yang; Yun-Song Yu; Ze-Qing Wei; Lan-Juan Li
Journal:  J Clin Microbiol       Date:  2007-10-17       Impact factor: 5.948

2.  Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii.

Authors:  Rajbharan Yadav; Cornelia B Landersdorfer; Roger L Nation; John D Boyce; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

3.  Antimicrobial activity of the imipenem/rifampicin combination against clinical isolates of Acinetobacter baumannii grown in planktonic and biofilm cultures.

Authors:  Yang Wang; Wanguo Bao; Na Guo; Haiying Chen; Wei Cheng; Kunqi Jin; Fengge Shen; Jiancheng Xu; Qiaoli Zhang; Chao Wang; Yanan An; Kaiyu Zhang; Feng Wang; Lu Yu
Journal:  World J Microbiol Biotechnol       Date:  2014-10-09       Impact factor: 3.312

4.  Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.

Authors:  C Routsi; M Pratikaki; E Platsouka; C Sotiropoulou; S Nanas; V Markaki; C Vrettou; O Paniara; H Giamarellou; C Roussos
Journal:  Infection       Date:  2010-03-12       Impact factor: 3.553

Review 5.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

6.  Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling.

Authors:  Cornelia B Landersdorfer; Rajbharan Yadav; Jürgen B Bulitta; Kate E Rogers; Tae Hwan Kim; Beom Soo Shin; John D Boyce; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

7.  Deciphering the function of the outer membrane protein OprD homologue of Acinetobacter baumannii.

Authors:  Manuella Catel-Ferreira; Rony Nehmé; Virginie Molle; Jesús Aranda; Emeline Bouffartigues; Sylvie Chevalier; Germán Bou; Thierry Jouenne; Emmanuelle Dé
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191

8.  Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.

Authors:  Anton Y Peleg; Jennifer Adams; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2007-04-09       Impact factor: 5.191

Review 9.  Antimicrobial active herbal compounds against Acinetobacter baumannii and other pathogens.

Authors:  Vishvanath Tiwari; Ranita Roy; Monalisa Tiwari
Journal:  Front Microbiol       Date:  2015-06-18       Impact factor: 5.640

10.  Clinical Specimen-Direct LAMP: A Useful Tool for the Surveillance of blaOXA-23-Positive Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Norihisa Yamamoto; Shigeto Hamaguchi; Yukihiro Akeda; Pitak Santanirand; Anusak Kerdsin; Masafumi Seki; Yoshikazu Ishii; Wantana Paveenkittiporn; Robert A Bonomo; Kazunori Oishi; Kumthorn Malathum; Kazunori Tomono
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.